Bicara Therapeutics Inc. ...

NASDAQ: BCAX · Real-Time Price · USD
11.43
0.10 (0.88%)
At close: Aug 14, 2025, 3:59 PM
11.41
-0.17%
Pre-market: Aug 15, 2025, 08:45 AM EDT

Bicara Therapeutics Common Stock Statistics

Share Statistics

Bicara Therapeutics Common Stock has 54.54M shares outstanding. The number of shares has increased by 5.36% in one year.

54.54M
5.36%
0.22%
81.29%
30.84M
560
0.07%

Short Selling Information

The latest short interest is 5.64M, so 10.35% of the outstanding shares have been sold short.

5.64M
10.35%
16.2%
12.78

Valuation Ratios

The PE ratio is -13.94 and the forward PE ratio is -3.76. Bicara Therapeutics Common Stock's PEG ratio is -0.56.

-13.94
-3.76
0
n/a
1.93
-12.67
-0.56
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Bicara Therapeutics Common Stock.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 27.93, with a Debt / Equity ratio of 0.

27.93
27.93
0
-0.01
-0.01
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-1.24M
55
0
n/a

Taxes

187K
-0.28%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is -1.49, so Bicara Therapeutics Common Stock's price volatility has been lower than the market average.

-1.49
n/a
10.43
14.3
43.72
790,769

Income Statement

n/a
n/a
-82.39M
-68M
-67.75M
-67.81M
-1.25
Full Income Statement

Balance Sheet

The company has 489.71M in cash and 738K in debt, giving a net cash position of 488.97M.

489.71M
738K
488.97M
-221.02M
478.08M
451.63M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -74.75M and capital expenditures -71K, giving a free cash flow of -74.82M.

-74.75M
-71K
-74.82M
-1.37
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

BCAX does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for BCAX is $33, which is 231.7% higher than the current price. The consensus rating is "Buy".

$33
231.7%
Buy
7
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

17.1
2